Correlation of long non-coding RNA <i>H19</i> expression with cisplatin-resistance and clinical outcome in lung adenocarcinoma
Qi Wang(Shanghai Pulmonary Hospital), Caicun Zhou(Tongji University), Ningning Cheng(Tongji University), Xuefei Li(Chengdu University of Traditional Chinese Medicine), Hui Pan(Inserm), Chunyu Li(Tianjin University of Traditional Chinese Medicine), Limin Zhang(Tongji Hospital), Chao Zhao(Tongji University), Shengxiang Ren(Tongji University), Weijing Cai(Icahn School of Medicine at Mount Sinai), Chunxia Su(Tongji University)
Cited by 77
Related Papers
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
|The Lancet|2021|1.5k
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial
|The Lancet Respiratory Medicine|2020|504